ImmuneOncia Therapeutics, Inc.
KOSDAQ-listed immuno-oncology biotech that out-licensed its Anti-PD-L1 antibody IMC-002 to China's 3D Medicines and partnered with Yuhan for Korean distribution.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2016 and listed on KOSDAQ in 2025, ImmuneOncia is an antibody-based immuno-oncology drug developer. It holds Anti-PD-L1, Anti-CD47, and Anti-LAG-3 monoclonal antibodies as core assets, and pursues a business model of developing drug candidates and out-licensing them at early clinical stages. In March 2021 it out-licensed IMC-002 (Anti-PD-L1) to China's 3D Medicines Biotechnology Shanghai Co, Ltd. for an upfront payment of USD 8 million (USD 7.5 million received), and in February 2024 it signed an exclusive patent license agreement with Yuhan Corporation for PD-L1 improved and antibody products (running royalty of 15% of net profit), while in September 2016 it signed an exclusive Korean distribution agreement with Yuhan for PD-L1.
Clinical trials
data.go.kr5 MFDS clinical trial authorisations · 2018–2022 (Phase 1 3 · Phase 2 2)
- Phase 2IMC-0012022-07-20
4 trial sites
- Phase 1IMC-0022022-03-08
3 trial sites
- Phase 1IMC-0022021-03-09
1 trial site
- Phase 2IMC-0012020-05-21
8 trial sites
- Phase 1IMC-0012018-02-01
2 trial sites
R&D and key agreements
Source: DART corporate disclosureIMC-002 · 임상1b상(계약당시 임상1상) · Anti-PD-L1 monoclonal antibody
Anti-CD47 · Core monoclonal antibody asset
Anti-LAG-3 · Core monoclonal antibody asset
AI reads
MAA server logs · IP-verifiedSomeone asked an AI a question, and it fetched this page live to answer.
Collected for later use. Not a signal of interest.
- OpenAIChatGPT-Useranswer2
- PerplexityPerplexityBot1
Measured since Aug 25, 2026 · 2 AI engines · last read Aug 26, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition